Free Trial

Hemogenyx Pharmaceuticals (HEMO) Competitors

Hemogenyx Pharmaceuticals logo
GBX 172.50 +1.50 (+0.88%)
As of 04/17/2025 11:50 AM Eastern

HEMO vs. OKYO, SAR, AOR, OPTI, AREC, RLM, POLB, NSCI, IMM, and SNG

Should you be buying Hemogenyx Pharmaceuticals stock or one of its competitors? The main competitors of Hemogenyx Pharmaceuticals include OKYO Pharma (OKYO), Sareum (SAR), AorTech International (AOR), OptiBiotix Health (OPTI), Arecor Therapeutics (AREC), Realm Therapeutics (RLM), Poolbeg Pharma (POLB), NetScientific (NSCI), ImmuPharma (IMM), and Synairgen (SNG). These companies are all part of the "biotechnology" industry.

Hemogenyx Pharmaceuticals vs.

OKYO Pharma (LON:OKYO) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, community ranking, risk, valuation, profitability, institutional ownership and earnings.

Hemogenyx Pharmaceuticals received 48 more outperform votes than OKYO Pharma when rated by MarketBeat users. However, 63.64% of users gave OKYO Pharma an outperform vote while only 57.89% of users gave Hemogenyx Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
OKYO PharmaOutperform Votes
7
63.64%
Underperform Votes
4
36.36%
Hemogenyx PharmaceuticalsOutperform Votes
55
57.89%
Underperform Votes
40
42.11%

0.8% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 31.9% of OKYO Pharma shares are held by insiders. Comparatively, 10.7% of Hemogenyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

OKYO Pharma has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500. Comparatively, Hemogenyx Pharmaceuticals has a beta of 3.14, meaning that its share price is 214% more volatile than the S&P 500.

Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than OKYO Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OKYO PharmaN/AN/A-£6.70M-£0.01N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£0.20-882.43

In the previous week, OKYO Pharma's average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
OKYO Pharma Neutral
Hemogenyx Pharmaceuticals Neutral

Hemogenyx Pharmaceuticals' return on equity of -80.66% beat OKYO Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
OKYO PharmaN/A -397.13% -154.72%
Hemogenyx Pharmaceuticals N/A -80.66%-37.79%

Summary

Hemogenyx Pharmaceuticals beats OKYO Pharma on 6 of the 10 factors compared between the two stocks.

Get Hemogenyx Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HEMO vs. The Competition

MetricHemogenyx PharmaceuticalsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£6.15M£120.88M£5.31B£2.52B
Dividend YieldN/A3.76%5.45%4.80%
P/E Ratio-882.433.0521.94130.99
Price / SalesN/A4,157.44380.66234,951.35
Price / Cash2.0513.0538.2528.35
Price / Book700.2034.176.454.43
Net Income-£6,890.55-£91.72M£3.22B£5.88B
7 Day Performance2.37%2.15%5.85%2.87%
1 Month Performance-2.89%-6.03%-9.62%-0.96%
1 Year Performance10,411.88%84.27%11.79%22.28%

Hemogenyx Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 172.50
+0.9%
N/A+10,411.9%£6.15MN/A-882.4314
OKYO
OKYO Pharma
N/AN/AN/AN/A£23.24MN/A-140.007Gap Down
SAR
Sareum
N/AGBX 18
-5.3%
N/AN/A£22.49MN/A-4.263,211Gap Up
AOR
AorTech International
N/AN/AN/AN/A£19.99M£539,000.00-33.383
OPTI
OptiBiotix Health
N/AGBX 18
+2.9%
N/A+2.8%£17.63M£590,009.23-5.701
AREC
Arecor Therapeutics
N/AGBX 38.50
+1.3%
N/A-69.3%£14.54M£6.04M-1.3610Gap Up
High Trading Volume
RLM
Realm Therapeutics
N/AN/AN/AN/A£13.41M£501,919.00-0.66N/A
POLB
Poolbeg Pharma
N/AGBX 2.54
-4.2%
N/A-74.5%£13.06MN/A0.0012Gap Down
NSCI
NetScientific
N/AN/AN/AN/A£12.81M£1.45M-486.3626
IMM
ImmuPharma
N/AGBX 2.37
-8.9%
N/A+2.6%£10.07M£-71,310.29-4.1013Gap Down
SNG
Synairgen
N/AGBX 0.93
-2.6%
N/A-86.3%£9.04MN/A-0.5634Gap Down

Related Companies and Tools


This page (LON:HEMO) was last updated on 4/21/2025 by MarketBeat.com Staff
From Our Partners